Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

The contents of cannabis plants are both psychoactive and nutritious. Today, extracts from the cannabis plant are ingredients ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

A new study reveals that junk food and drug use are hindering life expectancy gains in the U.S., despite technological ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...